$ALXO News
Last published 2mo ago
- 2mo agoALXOWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ALX ONCOLOGY HOLDINGS INCEarnings Call Transcriptsdiscussion. My name is Derek Archula. I'm one of the senior biotech analysts here at Wells. I'm very excited to have ALX Oncology joining me for the next panel here. From the company, we have Jason Letman, CEO, as well a
- 2mo agoALXOWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ALX ONCOLOGY HOLDINGS INCEarnings Call Transcriptsdiscussion. My name is Derek Archula. I'm one of the senior biotech analysts here at Wells. I'm very excited to have ALX Oncology joining me for the next panel here. From the company, we have Jason Letman, CEO, as well a
- 2mo agoALXOALX Oncology to Present at Upcoming Investor Conferences in SeptemberGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
- 3mo agoALXOALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast
- 4mo agoALXOALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing RulesGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology, ", NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
- 4mo agoALXOALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General CounselGlobeNewswireStrengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO,
- 5mo agoALXOJefferies Global Healthcare Conference in New York - ALX ONCOLOGY HOLDINGS INCEarnings Call TranscriptsAll right. Welcome, everyone, to Jeffrey's 2026 Global Healthcare Conference. My name is Roger Song, senior analyst at CoverSmithKai Biotech. It is my pleasure to have a next fireside chat with AOX Oncology. So welcome,
- 5mo agoALXOALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New YorkGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer
- 6mo agoALXOALX Oncology First Quarter 2026 Financial Results Conference Call & Webcast - ALX ONCOLOGY HOLDINGS INCEarnings Call TranscriptsGreetings and welcome to the ALX Oncology First Quarter 2026 Financial Results Conference and Webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presen
- 6mo agoALXOALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this
- 6mo agoALXOALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 ExpressionGlobeNewswire- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06
- 6mo agoALXOALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026GlobeNewswire- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", ,
- 6mo agoALXOALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing RulesGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (("ALX Oncology, NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat
- 7mo agoALXOALX Oncology Appoints Jeff Knight as Chief Development and Operating OfficerGlobeNewswire- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE
- 8mo agoALXOALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple
- 8mo agoALXOALX Oncology to Present at Upcoming Investor Conferences in Q1 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to
- 8mo agoALXOALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
- 9mo agoALXOALX Oncology Announces Pricing of Underwritten OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (("ALX Oncology, NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat
- 9mo agoALXONew Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast CancerGlobeNewswire- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full data set submitted
- 10mo agoALXOALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ((", ALX Oncology", , NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
- 10mo agoALXOALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004GlobeNewswire- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated
- 11mo agoALXOALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual MeetingGlobeNewswire- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50%
- 11mo agoALXOERASIMRXONCY+1Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106BGlobeNewswirePALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies
- 11mo agoALXOALX Oncology to Present at Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of
- 1y agoALXOALX Oncology Third Quarter 2025 Financial Results Conference Call & Webcast - ALX ONCOLOGY HOLDINGS INCEarnings Call TranscriptsGreetings and welcome to the ALX Oncology third quarter 2025 financial results conference call-in webcast. At this time all participants are in a listen-only mode. A question and answer session will follow the formal pre
- 1y agoALXOALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast Cancer
- 1y agoALXOALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of
- 1y agoALXOALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC ConferenceGlobeNewswire-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports
- 1y agoALXOALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireCompany will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company's lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025
- 1y agoALXOALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical OfficerGlobeNewswireDr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX
- 1y agoALXOALX Oncology to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of
- 1y agoALXOALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid TumorsGlobeNewswire- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window
- 1y agoALXOALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoALXOALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2
- 1y agoALXOALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of
- 1y agoALXOALX Oncology to Present at the Jefferies 2025 Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of
- 1y agoALXOALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast EventGlobeNewswire- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by
- 1y agoALXOALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of
- 1y agoALXOALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireFollowing announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC
- 1y agoALXOALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies
- 1y agoALXOALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin LymphomaGlobeNewswire- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising
- 1y agoALXOALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary EndpointsGlobeNewswireIn ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains confident in
- 1y agoALXOALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug ConjugateGlobeNewswireALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology's proprietary linker-payload platformALX2004, the
- 1y agoONCYEXELCRDFALXO+1Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the ChargePR NewswireAs the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...
- 1y agoALXOALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswire– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025
- 1y agoALXOALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast EventGlobeNewswireEvent to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancersAdvancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate,
- 1y agoALXOALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the
- 1y agoALXOALX Oncology to Host Virtual R&D Day on March 5, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the
- 1y agoONCYAGENGHXLO+2Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers SymposiumPR NewswireUSA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January 23-25...
- 1y agoALXOALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of DirectorsGlobeNewswireMr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug